Imexon
From Self-sufficiency
Revision as of 12:50, 28 August 2009 by JaGa (Talk) (Fixing links to disambiguation pages using AWB)
| File:Imexon.svg | |
| Systematic (IUPAC) name | |
|---|---|
|
4-imino-1,3-diazabicyclo[3.1.0]hexan-2-one | |
| Identifiers | |
| CAS Number | 59643-91-3 |
| ATC code | none |
| PubChem | CID 68791 |
| Chemical data | |
| Formula | C4H5N3O |
| Molar mass | 111.102 g/mol[[Script error: No such module "String".]] |
Imexon (INN, trade name Amplimexon) is a substance that is being studied in the treatment of some types of cancer, including pancreatic, lung, breast, prostate, melanoma, and multiple myeloma. It is a cyanoaziridine derivative.
External links
- Amplimexon entry in the public domain NCI Dictionary of Cancer Terms
This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".
| 35px | This oncology article is a stub. You can help ssf by expanding it. |
 |
This pharmacology-related article is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Wikipedia articles incorporating text from the National Cancer Institute Dictionary of Cancer Terms
- Chemotherapeutic agents
- Oncology stubs
- Pharmacology stubs
- 2Fix
